Drug Trial Radar · NCT07702656
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Sep 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of SYS6026 at different doses compared to placebo in treating patients with HPV16 or 18-related high-grade cervical squamous intraepithelial lesions (HSIL).
Conditions
- High-grade Cervical Intraepithelial Lesions
Interventions
SYS6026Biological
Administration continued until D168
PlaceboBiological
Administration continued until D168
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants whose pathology had resolved/remission to CIN1 and HPV16/18 negative at 36 weeks post-vaccination (independent pathology review)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CSPC Megalith Biopharmaceutical Co., Ltd.
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.